To the best of our knowledge, our study, for the first time, prepared ILs encapsulating a small quantity of the highly potent cytotoxin TNM A, showing superior selectivity against HER2‐positive breast cancer cells at single‐digit nanomolar concentrations (Figure 2). This evidence concerns the gene ERBB2 and breast carcinoma.